drugset / Trial / NCT00758303

A Study to Evaluate the Lipid Regulating Effects of TRIA-662

NCT00758303

Phase 2/3 Completed 211 enrolled Cortria Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of TRIA-662 (also known as 1-MNA) in treating elevated triglyceride levels in patients not receiving lipid lowering treatment. This study will determine the effects of TRIA-662 on commonly measured blood fats that are known to be important in the prevention of vascular disease.

Timeline

Start
2007-09
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator TRIGONELLAMIDE Small molecule 30 mg
Comparator TRIGONELLAMIDE Small molecule 90 mg

Indications